Although benefits of this approach on clinical endpoints were questionable in a small-sample-size study [29], in face of the knowledge that phosphate excess is responsible for the overproduction of PTH and FGF-23, it is reasonable to maintain levels of phosphate as low as possible in patients with CKD [30]. The gene discussed is FGF23; the disease is chronic kidney disease.